COVID-19 Vaccine(Janssen) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This COVID-19 Vaccine(Janssen) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
57
Registered trials
19
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether COVID-19 Vaccine(Janssen) can convert its Recombinant vector vaccine, Prophylactic vaccine profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | COVID-19 Vaccine(Janssen) (query alias: Ad26.COV2.S) |
|---|---|
| Modality / target | Recombinant vector vaccine, Prophylactic vaccine; SARS-CoV-2 S protein; SARS-CoV-2 S protein inhibitors |
| Highest global status | Approved |
| Originator | Janssen Vaccines & Prevention BV |
| Active developers | Janssen-Cilag Pty Ltd., Janssen Pharmaceuticals, Inc., Janssen Pharmaceutical KK |
The MCP disease footprint includes COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| PACTR202312739012205 | Phase 3 | Other | 500000 | Not disclosed |
| PACTR202310615330649 | Phase 3 | Other | 15000 | Not disclosed |
| NCT07408297 | Phase 2 | Completed | 1919 | Solicited Local Adverse Events |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial
Phase 2; n=694; evaluation: Positive. Reported fields: GMFC(neutralising antibodies at day 15) = 10.0 fold ( 8.6 - 11.7)
Immunogenicity and Safety of Heterologous <i>Versus</i> Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique
Phase 4; n=367; evaluation: Non-inferior. Reported fields: Geometric mean titers (GMTs) of anti-SARS-CoV-2 neutralizing antibodies(Omicron variant BA.1; 4 weeks after second vaccination) = 725.7 IU/mL ( 539.5 - 976.1); Geometric mean titers (GMTs) of anti-SARS-CoV-2 neutralizing antibodies(Omicron variant BA.1; 4 weeks after second vaccination) = 202.6 IU/mL ( 150.8 - 272.1); Geometric mean titers (GMTs) of anti-SARS-CoV-2 neutralizing antibodies(Omicron variant BA.1; 4 weeks after second vaccination) = 802.7 IU/mL ( 635.3 - 1014.3)
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants
Phase 2; n=51; evaluation: not stated. Reported fields: -; Number of Adult Participants With Solicited Local Adverse Events (AEs) for 7 Days Post First Vaccination = 5 Participants ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
COVID-19 Vaccine(Janssen) addresses COVID-19. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Recombinant vector vaccine, Prophylactic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-03-30 | Rega Institute is set to perform antiviral screening on Johnson & Johnson's compound libraries, which includes a vaccine for COVID-19. | Preclinical | Financial terms not disclosed |
| 2020-03-13 | Janssen Pharmaceutical and Beth Israel Deaconess Medical Center collaborate to develop a COVID-19 vaccine. | Preclinical | Financial terms not disclosed |
| 2020-02-11 | Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
